
Covid-19 created the perfect storm for the pharma industry’s already challenged supply chain network. The pandemic augmented supply chain risk and exposed weak areas such as the lack of end-to-end visibility. That’s an observation from Daniel Carchedi, Senior Director of Business Development and Strategy, Microsoft Health and Life Sciences.
Carchedi led a panel discussion, “Digital ecosystems and how to future proof supply chains,” on how tech companies, such as Microsoft and Accenture, are closely collaborating with the pharma industry as they seek to repair and improve manufacturing supply chain issues exposed by the Covid-19 pandemic.
About the Author
EcoVadis is a purpose-driven company dedicated to embedding sustainability intelligence into every business decision worldwide. We offer a full range of solutions including IQ-Plus Risk & Compliance Management, EcoVadis Ratings, and Carbon Action Module for Scope 3 Decarbonization. Key features like 360/Live News Monitoring, Academy E-learning and Corrective action plans help companies comply with ESG regulations, reduce GHG emissions, and improve the sustainability performance of their business and value chain across 250 industries in 185 countries.
Follow on Linkedin
Visit Website
More Content by EcoVadis EN